HC Wainwright Has Negative Estimate for CNTX FY2024 Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – Research analysts at HC Wainwright lowered their FY2024 earnings estimates for shares of Context Therapeutics in a research report issued to clients and investors on Thursday, November 7th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.53) per share for the year, down from their previous forecast of ($0.52). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q4 2024 earnings at ($0.04) EPS, FY2025 earnings at ($0.37) EPS, FY2026 earnings at ($0.52) EPS and FY2027 earnings at ($0.64) EPS.

Context Therapeutics Price Performance

Shares of NASDAQ:CNTX opened at $2.04 on Monday. Context Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.75. The stock has a market capitalization of $153.00 million, a price-to-earnings ratio of -2.26 and a beta of 2.25. The business’s fifty day moving average price is $2.09 and its two-hundred day moving average price is $2.07.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.11).

Institutional Trading of Context Therapeutics

Several hedge funds have recently modified their holdings of CNTX. Renaissance Technologies LLC boosted its holdings in shares of Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after acquiring an additional 25,300 shares in the last quarter. Opaleye Management Inc. raised its position in Context Therapeutics by 13.7% in the 1st quarter. Opaleye Management Inc. now owns 1,108,357 shares of the company’s stock valued at $1,530,000 after purchasing an additional 133,357 shares during the last quarter. Ally Bridge Group NY LLC boosted its stake in Context Therapeutics by 159.8% in the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after purchasing an additional 1,160,281 shares in the last quarter. Affinity Asset Advisors LLC grew its holdings in shares of Context Therapeutics by 392.4% during the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,290,323 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new stake in shares of Context Therapeutics in the second quarter valued at $3,881,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.